View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
December 10, 2018

Generon reports positive data from breast cancer drug trial

Generon BioMed has reported positive results from a Phase III trial of F-627 for the treatment of women with breast cancer.

Generon BioMed has reported positive results from a Phase III trial of F-627 for the treatment of women with breast cancer.

The global, double-blind, placebo controlled trial was led by the University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center.

It included 122 women with stage II-IV breast cancer receiving myelotoxic chemotherapy.

Results showed that subcutaneous administration of F-627 reduced the duration of Grade 4 or severe neutropenia in the trial’s chemotherapy cycle I.

Administration of F-627 also reduced the incidence and shorter duration of Grade IIII, Grade III and Grade II neutropenia.

“Generon is committed to bringing innovative oncology therapies to patients in China and the world.”

The trial showed that F-627 significantly reduced the incidence of febrile neutropenia (FN) among the subjects.

F-627 was also found to be safe and well tolerated with no deaths, no injection site reactions and reduced gastrointestinal after effects (AEs).

Generon BioMed chief medical officer Dr William Daley said: “This is yet another milestone and goal for Generon this year and is a significant step towards our mission of innovating for life.

“Generon is committed to bringing innovative oncology therapies to patients in China and the world.”

F-627 is a recombinant human Granulocyte Colony Stimulating Factor (rhG-CSF) protein developed for use as a preventive management of neutropenia.

Generon has used its Dimeric Cytokine (DiKine) technology to create F-627, which features an immunoglobulin-like dimeric structure.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena